TIME AND DATE: 12:00 p.m., Monday, August 6, 2007.

**PLACE:** Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551. **STATUS:** Closed.

#### MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

FOR FURTHER INFORMATION CONTACT: Michelle Smith, Director, or Dave Skidmore, Assistant to the Board, Office of Board Members at 202–452–2955.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at *http:// www.federalreserve.gov* for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Board of Governors of the Federal Reserve System, July 27, 2007.

# Robert deV. Frierson,

Deputy Secretary of the Board. [FR Doc. 07–3757 Filed 7–27–07; 3:57 pm] BILLING CODE 6210–01–S

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Office of the National Coordinator for Health Information Technology; American Health Information Community Personalized Healthcare Workgroup Meeting

#### **ACTION:** Announcement of meeting.

**SUMMARY:** This notice announces the seventh meeting of the American Health Information Community Personalized Healthcare Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.).

**DATES:** August 17, 2007, from 1 p.m. to 4 p.m. [Eastern Daylight Time].

**ADDRESSES:** Mary C. Switzer Building (330 C Street, SW., Washington, DC 20201), Conference Room 4090 (please bring photo ID for entry to a Federal building).

**FOR FURTHER INFORMATION CONTACT:** *http://www.hhs.gov/healthit/ahic/ healthcare/.*  **SUPPLEMENTARY INFORMATION:** The Workgroup will discuss possible common data standards to incorporate interoperable, clinically useful genetic laboratory test data, family history information, and analytical tools into Electronic Health Records (EHR) to support clinical decision-making for the health care provider and patient.

The meeting will be available via Web cast. For additional information, go to: http://www.hhs.gov/healthit/ahic/ healthcare/phc\_instruct.html.

Dated: July 20, 2007.

#### Judith Sparrow,

Director, American Health Information Community, Office of Programs and Coordination, Office of the National Coordinator for Health Information Technology.

[FR Doc. 07–3715 Filed 7–30–07; 8:45 am] BILLING CODE 4150–24–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the National Coordinator for Health Information Technology; American Health Information Community Quality Workgroup Meeting

**ACTION:** Announcement of meeting.

**SUMMARY:** This notice announces the 11th meeting of the American Health Information Community Quality Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. No. 92–463, 5 U.S.C., App.).

**DATES:** August 30, 2007, from 1 p.m. to 4 p.m. [Eastern].

**ADDRESSES:** Mary C. Switzer Building (330 C Street, SW., Washington, DC 20201), Conference Room 4090 (please bring photo ID for entry to a Federal building).

# FOR FURTHER INFORMATION CONTACT:

http://www.hhs.gov/healthit/ahic/ quality/.

**SUPPLEMENTARY INFORMATION:** The Workgroup will continue its discussion on how health information technology can provide the data needed for the development of quality measures that are useful to patients and others in the health care industry, automate the measurement and reporting of a comprehensive current and future set of quality measures, and accelerate the use of clinical decision support that can improve performance on those quality measures.

The meeting will be available via Web cast. For additional information, go to: http://www.hhs.gov/healthit/ahic/ quality\_instruct.html. Dated: July 20, 2007. Judith Sparrow,

Director, American Health Information Community, Office of Programs and Coordination, Office of the National Coordinator for Health Information Technology. [FR Doc. 07–3716 Filed 7–30–07; 8:45 am]

BILLING CODE 4150-24-M

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Toxicology Program (NTP); Report on Carcinogens (RoC) Availability of the Draft Background Documents on Captafol and ortho-Nitrotoluene and Request for Public Comment on the Draft Background Documents; Announcement of the Captafol and the ortho-Nitrotoluene Expert Panel Meeting

**AGENCY:** National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH).

**ACTION:** Request for public comments and meeting announcement.

SUMMARY: The NTP announces the availability of the draft background documents for captafol and orthonitrotoluene on August 1, 2007, from the RoC Web site (*http://* ntp.niehs.nih.gov/go/10091 see captafol or ortho-nitrotoluene) or in printed text from the RoC (see FOR FURTHER **INFORMATION CONTACT** below). The NTP invites the submission of public comments on the two draft background documents (see SUPPLEMENTARY **INFORMATION** below). The expert panel will meet on October 15-16, 2007, at the Sheraton Chapel Hill Hotel, Chapel Hill, North Carolina, to peer review the draft background documents for captafol and ortho-nitrotoluene and once completed make a recommendation regarding the listing status (i.e., known to be a human carcinogen, reasonably anticipated to be a human carcinogen, or not to list) for captafol and ortho-nitrotoluene in the 12th Edition of the RoC (12th RoC). The RoC expert panel meeting is open to the public with time scheduled for oral public comments. Attendance is limited only by the available meeting room space. Following the expert panel meeting and completion of the expert panel report, the NTP will post the final version of the background documents and the expert panel peer review reports on the RoC Web site.

**DATES:** The expert panel meeting for captafol and ortho-nitrotoluene will be held on October 15–16, 2007. The draft background documents for these

substances will be available for public comment on August 1, 2007. The deadline to submit written comments is October 3, 2007, and the deadline for pre-registration to attend the meeting and provide oral comments at the meeting is October 10, 2007. Persons needing special assistance, such as sign language interpretation or other reasonable accommodation in order to attend, should contact 919-541-2475 (voice), 919-541-4644 TTY (text telephone), through the Federal TTY Relay System at 800-877-8339, or by e-mail to: niehsoeeo@niehs.nih.gov. Requests should be made at least seven business days in advance of the event.

ADDRESSES: The RoC expert panel meeting on captafol and orthonitrotoluene will be held at the Sheraton Chapel Hill Hotel [One Europa Drive, Chapel Hill, North Carolina 27514, Phone: (919) 968–4900 FAX: (919) 968– 3520]. Access to on-line registration and materials for the meeting is available on the RoC Web site: (*http://* 

ntp.niehs.nih.gov/go/roc see Expert Panel Meetings). Comments on the draft background documents should be sent to Dr. C.W. Jameson, RoC Director, NIEHS, P.O. Box 12233, MD EC–14, Research Triangle Park, NC 27709, FAX: (919) 541–0144, or

*jameson@niehs.nih.gov.* Courier address: Report on Carcinogens, 79 T.W. Alexander Drive, Building 4401, Room 3118, Research Triangle Park, NC 27709.

FOR FURTHER INFORMATION CONTACT: Dr. C.W. Jameson, RoC Director, 919–541– 4096, *jameson@niehs.nih.gov*. SUPPLEMENTARY INFORMATION:

#### Background

On April 16, 2007 (72 FR 18999 available at http://ntp.niehs.nih.gov/go/ 9732), NTP announced the RoC review process for the 12th RoC. Captafol and ortho-nitrotoluene are the first two substances (of a total of 14 candidate substances) to undergo formal review. The draft background documents for these two candidate substances will be available on the RoC Web site on August 1, 2007, or in printed text from the RoC Director (see ADDRESSES above). Availability of the draft background documents for other candidate substances will be announced via the NTP listserv and on the RoC Web site and expert panel meetings to review these substances will be announced via the Federal Register. Persons can register free-of-charge with the NTP listserv to receive notification when draft background documents are posted (http://ntp.niehs.nih.gov/go/231).

Captafol (CAS RN: 2425–06–1) is a broad-spectrum fungicide that was

widely used in the United States prior to the mid 1980s on fruits, vegetables, and other plants, as well as on timber products. In 1999, the U.S. Environmental Protection Agency revoked all captafol tolerances except those for onions, potatoes, and tomatoes. Although many countries have now banned its use, captafol is still registered in some countries (such as Mexico). The Food and Drug Administration continues to monitor for captafol residues in domestic and imported food. The potential exists for past, extensive exposure for workers producing captafol and for agricultural workers because of past production and use of millions of pounds of captafol.

Ortho-Nitrotoluene (CAS RN: 88–72– 2) is used to synthesize agricultural and organic chemicals, explosives, azo and sulfur dyes, and dyes for cotton, wool, silk, leather, and paper. ortho-Nitrotoluene is a high production volume (HPV) chemical, and its U.S. production was between 10 million and 50 million pounds for every four-year reporting period from 1986 to 2002. Exposure to ortho-nitrotoluene in the United States is primarily a result of occupational exposure during the production and use of this chemical.

### **Request for Comments**

The NTP invites written public comments on the draft background documents on captafol and orthonitrotoluene. All comments received will be posted on the RoC Web site prior to the meeting and distributed to the expert panel and RoC staff for their consideration in the peer review of the draft background documents and/or preparing for the expert panel meeting. Persons submitting written comments are asked to include their name and contact information (affiliation, mailing address, telephone and facsimile numbers, e-mail, and sponsoring organization, if any) and send them to Dr. Jameson (see ADDRESSES above) for receipt by October 3, 2007. Time is set aside on October 15-16, 2007, for the presentation of oral public comments at the expert panel meeting. Seven minutes will be available for each speaker (one speaker per organization). Persons can register on-line to present oral comments or contact Dr. Jameson (see ADDRESSES above). When registering to comment orally, please provide your name, affiliation, mailing address, telephone and facsimile numbers, email and sponsoring organization (if any). If possible, send a copy of the statement or talking points to Dr. Jameson by October 10, 2007. This statement will be provided to the expert panel to assist them in

identifying issues for discussion and will be noted in the meeting record. Registration for presentation of oral comments will also be available at the meeting on October 15–16, 2007, from 7:30–8:30 a.m. Persons registering at the meeting are asked to bring 25 copies of their statement or talking points for distribution to the expert panel and for the record.

### Preliminary Agenda, Availability of Meeting Topics and Registration

Preliminary agenda topics include:

• Oral public comments on captafol

• Peer review of the background document on captafol

• Recommendation for listing status for captafol in the 12th RoC

• Oral public comments on orthonitroluene

• Peer review of the background document on ortho-nitrotoluene

• Recommendation for listing status for ortho-nitrotoluene in the 12th RoC

The meeting is scheduled for October 15–16, 2007, from 8:30 a.m. to adjournment each day. The review of ortho-nitrotoluene will immediately follow the review of captafol. A copy of the preliminary agenda, expert panel roster, and any additional information, when available, will be posted on the RoC Web site or may be requested from the RoC Director (see **ADDRESSES** above). Individuals who plan to attend the meeting are encouraged to register online by October 10, 2007, to facilitate planning for the meeting.

# **Background Information on the RoC**

The RoC is a Congressionally mandated document that identifies and discusses agents, substances, mixtures, or exposure circumstances (collectively referred to as "substances") that may pose a hazard to human health by virtue of their carcinogenicity. Substances are listed in the report as either known or reasonably anticipated human carcinogens. The NTP prepares the RoC on behalf of the Secretary of Health and Human Services. Information about the RoC and the nomination process can be obtained from its homepage (http:// *ntp.niehs.nih.gov/go/roc*) or by contacting Dr. Jameson (see FOR FURTHER **INFORMATION CONTACT** above). The NTP follows a formal, multi-step process for review and evaluation of selected chemicals. The formal evaluation process is available on the RoC Web site: (http://ntp.niehs.nih.gov/go/15208) or in printed copy from the RoC Director.

Dated: July 20, 2007.

David A. Schwartz, Director, National Institute of Environmental Health Sciences, and National Toxicology Program.

[FR Doc. E7–14689 Filed 7–30–07; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Agency for Healthcare Research and Quality

# **Notice of Meeting**

In accordance with section 10(d) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2), announcement is made of Health Care Policy and Research Special Emphasis Panel (SEP) meeting.

A Special Emphasis Panel is a group of experts in fields related to health care research who are invited by the Agency for Healthcare Research and Quality (AHRQ), and agree to be available, to conduct on an as needed basis, scientific reviews of applications for AHRQ support. Individual members of the Panel do not attend regularlyscheduled meetings and do not serve for fixed terms or a long period of time. Rather, they are asked to participate in particular review meetings which require their type of expertise.

Substantial segments of the upcoming SEP meeting listed below will be closed to the public in accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C. 552b(c)(6). Grant applications for the Announcement of Availability of Funds for Grants regarding Family Planning Services Delivery Improvement (SDI) Research are to be reviewed and discussed at this meeting. This program is sponsored by the Office of Populations Affairs. These discussions are likely to reveal personal information concerning individuals associated with the applications. This information is exempt from mandatory disclosure under the above-cited statutes.

*SEP Meeting on:* Family Planning Services Delivery Improvement (SDI) Research.

*Date:* August 23, 2007 (Open on August 23 from 8 a.m. to 8:15 a.m. and closed for the remainder of the meeting).

*Place:* John M. Eisenberg Building, AHRQ Conference Center, 540 Gaither Road, Rockville, Maryland 20850.

*Contact Person:* Anyone wishing to obtain a roster of members, agenda or minutes of the non-confidential portions of this meeting should contact Mrs. Bonnie Campbell, Committee Management Officer, Office of Extramural Research, Education and Priority Populations, HARQ, 540 Gaither Road, Room 2038, Rockville, Maryland 20850, Telephone (301) 427–1554.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: July 24, 2007.

# Carolyn M. Clancy,

Director. [FR Doc. 07–3706 Filed 7–30–07; 8:45 am] BILLING CODE 4160–90–M

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

#### [60Day-07-07BE]

#### Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404-639-5960 and send comments to Maryam I. Daneshvar, CDC Acting Reports Clearance Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

# **Proposed Project**

Research to Reduce Time to Treatment for Heart Attack/Myocardial Infraction for Rural American Indians/ Alaska Natives (AI/AN)—NEW— National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC).

#### Background and Brief Description

Every year, approximately 1.1 million Americans have a first or recurrent heart attack/myocardial infarction (MI) and about one third of these will be fatal. Early recognition of MI by both the victim and bystanders followed by prompt cardiac emergency and advanced care has a direct effect on patient outcomes (heart damage, morbidity and mortality): the shorter the delay to treatment, the better the outcomes. Results of a recent Behavioral Risk Factor Survey (BRFSS) survey showed that public recognition of major MI symptoms and the need for immediate action by calling 9–1–1 was poor and that there is a need for increased public health efforts. Patient delay accounts for most of the lag in treatment.

Data from the National MI Registry show that the greatest disparity for delay in treatment exists among the racial and ethnic groups of American Indian/Alaskan Native group. The NATIVE study shows that rural American Indians presenting with acute MI have marked delays in time to treatment (12% of patients waited between 12–24 hours and 23% waited more than 24 hours to present) thus, limiting treatment options; the primary cause of the delay was due to patient misunderstandings about the symptoms of MI.

The project will contribute to our understanding of AI/AN populations and their perceptions of and misconceptions about MI and the need for immediate treatment. Information gained from this project will provide the details needed to tailor message(s) for this population. The agency will develop culturally-tailored messages for native populations that will contribute to the existing National Heart Attack program (NHLBI) "Act in Time" messages.

There will be a minimum of 84 key informant interviews and 16 persons in the two focus groups. The key informants will consist of healthcare providers, community leader, and persons who have had an MI. Key informants will be identified for interviews through a clustered, multistate snowball sampling technique. In recognition of the tribal diversity; study participants will represent three AI/AN regions of the U.S.: Great Plains identified by the Aberdeen Area Indian Health Service area, the South West distinct to the Phoenix, Albuquerque and Tucson areas and Alaskan Natives. Interview participants will have established relationships with tribes or